Follow
Engineering T cells
Engineering T cells is a broad description of techniques used to modify a T cells obtained from a patient or healthy donor. T cells are a subset of immune cells responsible for targeting and killing tumor cells. Once harvested from a patient or donor, the T cells can be engineered in a laboratory making them better capable of killing a specific tumor. Examples of adoptive cell therapies using engineered T cells are T cell receptor (TCR)-engineered T cells and chimeric antigen receptor (CAR) T cells.
OCT 10, 2018 | 6:00 AM
Understanding the immune repertoire is an important aspect of immuno-oncology research, which can be used to gather insights into the function and overall status of the immune system. We have...
SEP 27, 2018 | 12:00 PM
There is considerable excitement surrounding the treatment potential of T cell immunotherapies. Amongst these, CAR-T cells have demonstrated impressive therapeutic efficacy in a subset of hem...
SEP 18, 2018 | 8:00 AM
DATE: September 18,2018TIME: 08:00am PDT, 11:00am EDT CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and sp...
SEP 13, 2018 | 1:30 PM
The soil microbiome can produce, resist, or degrade antibiotics and even catabolize them. Resistance genes are widely distributed in the soil and may act as a reservoir for pathogen antibioti...
JUN 28, 2018 | 8:00 AM
DATE: June 28, 2018TIME: 8:00AM PDTEnrichment of leukocytes from blood products like buffy coat, leukocyte reduction chambers (LRSC) or leukapheresis material can be time consuming...
MAY 30, 2018 | 10:30 AM
NSD2 catalyzes the mono- and di-methylation of the e-amine of lysine 36 from histone H3, utilizing the methyl donor S-adenosyl-L-methionine. Increased catalytic activity of NSD2, either by ov...
APR 26, 2018 | 8:00 AM
DATE: April 26, 2018TIME: 8:00am PST, 11:00am EST Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therap...
MAR 21, 2018 | 8:00 AM
DATE: March 21, 2018TIME: 8:00AM PST, 11:00AM ESTMass cytometry, or cytometry by time-of-flight (the basis of the CyTOF® system), enables quantification of the abundance and fu...
JAN 25, 2018 | 10:00 AM
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
JAN 25, 2018 | 8:00 AM
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
NOV 15, 2017 | 10:00 AM
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
NOV 07, 2017 | 10:00 AM
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
OCT 19, 2017 | 8:00 AM
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
